EphA2-Based Cell Sorting for Tumor Stem Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to efficiently isolate and obtain a population of mammalian tumor stem cells with undifferentiated and stable phenotypes that retain the capability to differentiate into multiple cell lineages, particularly in the context of brain tumors like glioblastoma multiforme, due to the lack of reliable cell markers for cancer stem cells.
Innovation Solution
A method involving cell sorting based on EphA2 expression levels to enrich for cancer stem cells or tumor-propagating cells, where cells with high EphA2 expression demonstrate higher tumor-propagating ability, allowing for the isolation of a population of mammalian tumor stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If cell sorting based on EphA2 expression is used to isolate tumor stem cells, then the purity and enrichment of cancer stem cells is improved, but the complexity of the isolation procedure increases
Solution Approach 1:
The patent uses fluorescent labeling of EphA2 marker expression on cell surfaces to enable optical detection and sorting. Cells expressing high levels of EphA2 are tagged with fluorescent markers, allowing flow cytometry to identify and separate these tumor-propagating cells from the heterogeneous tumor population based on their fluorescent signal intensity.
2Measurement precision
If cell sorting based on EphA2 expression is performed, then the capability to study tumor-propagating cells is improved, but the time required for cell isolation increases
Solution Approach 1:
The patent performs preliminary sorting of tumor cells based on EphA2 expression levels before functional assays. By pre-enriching the tumor-propagating cell population through EphA2-based flow cytometry sorting, subsequent experiments require fewer cells and less time to achieve statistically significant results, compensating for the initial sorting time investment.
3Adaptability or versatility
If a heterogeneous tumor population is studied, then the representation of tumor diversity is improved, but the ability to identify specific tumor-propagating cells deteriorates
Solution Approach 1:
The patent applies the concept of local quality by identifying that specific subpopulations within the heterogeneous tumor possess distinct molecular characteristics (high EphA2 expression). Rather than treating all tumor cells uniformly, the method selectively targets and isolates the specific subpopulation with elevated EphA2, which corresponds to tumor-propagating cells, while maintaining awareness of the overall tumor heterogeneity.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention concerns the field of stem cell biology, and in particular relates to a method for producing an isolated bona fide population of mammalian stem cells, and uses of the stem cells thus produced. Human glioblastomas (hGBMs) have now been shown to contain a minor subset of cells bearing the defining features of somatic stem cells (SCs) and the ability to establish, expand and perpetuate these tumors. They are defined stem-like tumor propagating cells (TPCs). This has caused a paradigmatic shift in the way we interpret hGBM physiology, for it identifies TPCs as a major culprit to be tackled for the development of novel therapeutics. It also suggests that studying the regulatory mechanisms of normal neurogenesis may point to specific inhibitors of TPCs.